HK1256269A1 - 溴區結構域抑制劑和檢查點阻斷的組合療法 - Google Patents

溴區結構域抑制劑和檢查點阻斷的組合療法

Info

Publication number
HK1256269A1
HK1256269A1 HK18115329.0A HK18115329A HK1256269A1 HK 1256269 A1 HK1256269 A1 HK 1256269A1 HK 18115329 A HK18115329 A HK 18115329A HK 1256269 A1 HK1256269 A1 HK 1256269A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
checkpoint blockade
bromodomain inhibitors
bromodomain
inhibitors
Prior art date
Application number
HK18115329.0A
Other languages
English (en)
Inventor
J‧E‧布拉德納
S‧J‧霍格
R‧W‧約翰斯頓
J‧肖特
Original Assignee
達納-法伯癌症研究所股份有限公司
彼得麥卡勒姆癌症研究中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 達納-法伯癌症研究所股份有限公司, 彼得麥卡勒姆癌症研究中心 filed Critical 達納-法伯癌症研究所股份有限公司
Publication of HK1256269A1 publication Critical patent/HK1256269A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18115329.0A 2015-10-02 2018-11-29 溴區結構域抑制劑和檢查點阻斷的組合療法 HK1256269A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236280P 2015-10-02 2015-10-02
PCT/US2016/054924 WO2017059319A2 (en) 2015-10-02 2016-09-30 Combination therapy of bromodomain inhibitors and checkpoint blockade

Publications (1)

Publication Number Publication Date
HK1256269A1 true HK1256269A1 (zh) 2019-09-20

Family

ID=57137298

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115329.0A HK1256269A1 (zh) 2015-10-02 2018-11-29 溴區結構域抑制劑和檢查點阻斷的組合療法

Country Status (16)

Country Link
US (1) US20190192532A1 (zh)
EP (1) EP3355922A2 (zh)
JP (1) JP2018530554A (zh)
KR (1) KR20180081507A (zh)
CN (1) CN108289957A (zh)
AR (1) AR107500A1 (zh)
AU (1) AU2016331190A1 (zh)
BR (1) BR112018006689A2 (zh)
CA (1) CA2999523A1 (zh)
CL (1) CL2018000853A1 (zh)
HK (1) HK1256269A1 (zh)
IL (1) IL258212A (zh)
MA (1) MA43037A (zh)
MX (1) MX2018003824A (zh)
PE (1) PE20181068A1 (zh)
WO (1) WO2017059319A2 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101514463B1 (ko) * 2005-06-08 2015-04-28 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
WO2010025421A2 (en) 2008-08-28 2010-03-04 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
ES2534521T3 (es) 2010-05-14 2015-04-23 Dana-Farber Cancer Institute, Inc. Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 白血病を治療するための組成物および方法
DK2877189T3 (da) 2012-07-20 2021-02-22 Taiga Biotechnologies Inc Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
BR112018074463A2 (pt) 2016-05-27 2019-03-06 Agenus Inc. anticorpos anti-tim-3 e métodos de uso dos mesmos.
IL281425B (en) 2016-12-02 2022-07-01 Taiga Biotechnologies Inc Nanoparticle formulations
WO2019140953A1 (zh) * 2018-01-16 2019-07-25 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的二苯氨基嘧啶类化合物
WO2020051571A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
CN109666723B (zh) * 2019-01-22 2022-04-15 南通大学 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用
AU2020274117A1 (en) * 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
WO2021011634A1 (en) * 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Protein degraders and uses thereof
MX2022005029A (es) * 2019-11-05 2022-07-12 Resverlogix Corp Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.
US20230053152A1 (en) * 2019-11-26 2023-02-16 Benobio Co., Ltd. Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor
TW202136251A (zh) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak降解劑及其用途
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
PE20231739A1 (es) 2020-07-02 2023-10-31 Incyte Corp Compuestos triciclicos de urea como inhibidores de jak2 v617f
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010314395B2 (en) * 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
CA2799381A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
ES2534521T3 (es) * 2010-05-14 2015-04-23 Dana-Farber Cancer Institute, Inc. Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades
WO2012075456A1 (en) * 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2958922A1 (de) * 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen
CN105164135A (zh) * 2013-02-22 2015-12-16 拜耳医药股份有限公司 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
WO2014144721A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
EP3030242A1 (en) * 2013-08-06 2016-06-15 Oncoethix GmbH Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
KR20160060765A (ko) * 2013-10-11 2016-05-30 제넨테크, 인크. 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도
MX369491B (es) * 2013-12-24 2019-11-11 Bristol Myers Squibb Co Compuestos tricíclicos como agentes anticancerígenos.

Also Published As

Publication number Publication date
WO2017059319A2 (en) 2017-04-06
BR112018006689A2 (pt) 2018-10-09
WO2017059319A3 (en) 2017-10-12
EP3355922A2 (en) 2018-08-08
AR107500A1 (es) 2018-05-09
US20190192532A1 (en) 2019-06-27
MX2018003824A (es) 2019-04-01
AU2016331190A1 (en) 2018-04-12
KR20180081507A (ko) 2018-07-16
IL258212A (en) 2018-05-31
CA2999523A1 (en) 2017-04-06
JP2018530554A (ja) 2018-10-18
CN108289957A (zh) 2018-07-17
CL2018000853A1 (es) 2018-08-31
MA43037A (fr) 2018-08-08
PE20181068A1 (es) 2018-07-04

Similar Documents

Publication Publication Date Title
HK1256269A1 (zh) 溴區結構域抑制劑和檢查點阻斷的組合療法
HK1256796A1 (zh) 二價溴結構域抑制劑及其用途
HK1256380A1 (zh) 修飾的細胞和治療方法
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
IL251669A0 (en) Cancer treatment using a tlr9 agonist with checkpoint inhibitors
IL265274A (en) Combined treatment of antibody and checkpoint inhibitor
HK1254129A1 (zh) 給予谷氨酰胺酶抑制劑的方法
IL258500A (en) Combination therapy with glutaminase inhibitors and immuno-oncology agents
IL260222A (en) Bromodomain and extra-terminal protein inhibitor combination therapy
IL256515A (en) Therapeutic peptides and methods of use thereof
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
HK1252567A1 (zh) 被取代的苯甲酰胺和其使用方法
IL265955A (en) Therapeutic compounds and methods of use thereof
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
EP3370773A4 (en) POLYTHERAPY COMPRISING IMMUNOTOXINS AND A CONTROL POINT INHIBITOR
PL3532059T3 (pl) Terapia skojarzona z zastosowaniem inhibitora białka bet
LT3370733T (lt) Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
HK1246689A1 (zh) 溴莫尼定和噻嗎洛爾的固定劑量組合
EP3325100A4 (en) COMBINED THERAPY USING PDK1 AND PI3K INHIBITORS
HK1245644B (zh) 投予特拉萬星的劑量和方法
HK1258056A1 (zh) 治療性化合物和其使用方法